Pharma Targeting Research Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 25.65%
(FY 2023)
- Profit -182.58%
(FY 2023)
- Ebitda -48.98%
(FY 2023)
- Net Worth -164.77%
(FY 2023)
- Total Assets 31.37%
(FY 2023)
About Pharma Targeting Research
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Anil Kumar, Neha Sandhu, and Sandeep Singh serve as directors at the Company.
- CIN/LLPIN
U74900MH2014PTC259578
- Company No.
259578
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Pharma Targeting Research?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar  | Managing Director | 20-Nov-2014 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neha Sandhu  | Director | Current | |
| Sandeep Singh | Director | 08-Nov-2016 | Current |
Financial Performance of Pharma Targeting Research.
Pharma Targeting Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.65% increase. The company also saw a substantial fall in profitability, with a 182.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 164.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharma Targeting Research?
Unlock access to Pharma Targeting Research's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharma Targeting Research?
Pharma Targeting Research has a workforce of 134 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharma Targeting Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharma Targeting Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
